We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Moderna projects Q2 sales of $127 million and a $2.99 per-share loss ahead of its Aug. 1 earnings release.
Spikevax sales are estimated to decline sharply, with limited revenue from the RSV vaccine, mResvia.
Investors await news on vaccine label expansions, regulatory filings, and late-stage trial results.
We expect Moderna (MRNA - Free Report) to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening bell. The company’s earnings beat estimates by 13.70% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $127 million and a loss of $2.99 per share, respectively.
Factors Shaping MRNA’s Upcoming Results
Moderna is likely to have generated a major portion of its revenues from selling its COVID-19 vaccine, Spikevax. Our model estimate for the vaccine’s sales is pegged at $59 million, implying a significant decline from the year-ago level due to lower demand.
We expect minimal product sales of the company's RSV vaccine mResvia, which received FDA approval last year. We estimate mResvia sales at just $2 million, far below sales of competing RSV vaccines, Arexvy (marketed by GSK) and Abrysvo (Pfizer). The softer sales expectation is likely due to the vaccine being approved and recommended later in the contracting season.
Last month, the FDA granted label expansion to mResvia for use in high-risk adults aged 18-59. Just a couple of weeks after this approval, the CDC broadened its RSV vaccine recommendations for this respiratory virus season to include high-risk adults aged 50-59. The prior guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Investors might seek updates from the company regarding its plans for marketing both vaccines in the upcoming season.
A regulatory filing is currently under FDA review seeking label approval for updating Spikevax to target the LP.8.1 variant for the 2025-26 vaccination season. A similar regulatory filing is also under the EMA’s review, which recently received a positive recommendation from the Committee for Medicinal Products for Human Use (“CHMP”). Investors would be keen to hear updates on the regulatory progress of these filings, including any feedback or requests for additional data from the FDA, during the upcoming earnings call.
Moderna is also evaluating several pipeline candidates in late-stage development. Last month, the company reported that a phase III efficacy study (P304) showed that its influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy to an approved flu shot marketed by GSK. These results not only support potential approval of the standalone flu shot but also strengthen the case for refiling mRNA-1083, an investigational combination vaccine against COVID-19 and influenza. In May, Moderna voluntarily withdrew a filing with the FDA for mRNA-1083 after the agency requested additional efficacy data for the flu component. This candidate integrates the company’s COVID-19 shot with mRNA-1010. Investors are likely to watch for updates on refiling plans.
An important candidate in the company’s pipeline is intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK - Free Report) . Moderna and Merck are evaluating the therapy in three pivotal phase III studies — one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in clinical studies for cutaneous squamous cell carcinoma, renal cell carcinoma and muscle-invasive bladder cancer indications. Investors might seek an update on the Merck-partnered therapy’s progress across these studies.
MRNA’s Earnings Surprise History
The biotech firm’s performance has been impressive over the past four quarters. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.60%.
Year to date, Moderna’s shares have declined 18% against the industry’s 2% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for MRNA
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is exactly the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some other biotech stocks that also have the right combination of elements to beat onearnings this time around:
BioNTech (BNTX - Free Report) currently has an Earnings ESP of +127.01% and a Zacks Rank of #1.
BNTX stock has lost 1% year to date. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 56.47%. BioNTech intends to report Q2 earnings on Aug. 4, before the opening bell.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have lost 15% year to date. It beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is expected to report Q2 results on Aug. 6, after market close.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?
Key Takeaways
We expect Moderna (MRNA - Free Report) to surpass expectations when it reports second-quarter 2025 earnings on Aug. 1, before the opening bell. The company’s earnings beat estimates by 13.70% in the last reported quarter.
The Zacks Consensus Estimate for sales and earnings is pegged at $127 million and a loss of $2.99 per share, respectively.
Factors Shaping MRNA’s Upcoming Results
Moderna is likely to have generated a major portion of its revenues from selling its COVID-19 vaccine, Spikevax. Our model estimate for the vaccine’s sales is pegged at $59 million, implying a significant decline from the year-ago level due to lower demand.
We expect minimal product sales of the company's RSV vaccine mResvia, which received FDA approval last year. We estimate mResvia sales at just $2 million, far below sales of competing RSV vaccines, Arexvy (marketed by GSK) and Abrysvo (Pfizer). The softer sales expectation is likely due to the vaccine being approved and recommended later in the contracting season.
Last month, the FDA granted label expansion to mResvia for use in high-risk adults aged 18-59. Just a couple of weeks after this approval, the CDC broadened its RSV vaccine recommendations for this respiratory virus season to include high-risk adults aged 50-59. The prior guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Investors might seek updates from the company regarding its plans for marketing both vaccines in the upcoming season.
A regulatory filing is currently under FDA review seeking label approval for updating Spikevax to target the LP.8.1 variant for the 2025-26 vaccination season. A similar regulatory filing is also under the EMA’s review, which recently received a positive recommendation from the Committee for Medicinal Products for Human Use (“CHMP”). Investors would be keen to hear updates on the regulatory progress of these filings, including any feedback or requests for additional data from the FDA, during the upcoming earnings call.
Moderna is also evaluating several pipeline candidates in late-stage development. Last month, the company reported that a phase III efficacy study (P304) showed that its influenza vaccine candidate, mRNA-1010, achieved superior relative vaccine efficacy to an approved flu shot marketed by GSK. These results not only support potential approval of the standalone flu shot but also strengthen the case for refiling mRNA-1083, an investigational combination vaccine against COVID-19 and influenza. In May, Moderna voluntarily withdrew a filing with the FDA for mRNA-1083 after the agency requested additional efficacy data for the flu component. This candidate integrates the company’s COVID-19 shot with mRNA-1010. Investors are likely to watch for updates on refiling plans.
An important candidate in the company’s pipeline is intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK - Free Report) . Moderna and Merck are evaluating the therapy in three pivotal phase III studies — one in the melanoma indication and the other two in the non-small cell lung cancer space. It is also being evaluated in clinical studies for cutaneous squamous cell carcinoma, renal cell carcinoma and muscle-invasive bladder cancer indications. Investors might seek an update on the Merck-partnered therapy’s progress across these studies.
MRNA’s Earnings Surprise History
The biotech firm’s performance has been impressive over the past four quarters. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 31.60%.
Moderna, Inc. Price and EPS Surprise
Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote
Year to date, Moderna’s shares have declined 18% against the industry’s 2% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for MRNA
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) have a good chance of delivering an earnings beat. This is exactly the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Moderna has an Earnings ESP of +7.22% and a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks With the Favorable Combination
Here are some other biotech stocks that also have the right combination of elements to beat onearnings this time around:
BioNTech (BNTX - Free Report) currently has an Earnings ESP of +127.01% and a Zacks Rank of #1.
BNTX stock has lost 1% year to date. It beat on earnings in three of the last four quarters and missed in the other one, delivering an average surprise of 56.47%. BioNTech intends to report Q2 earnings on Aug. 4, before the opening bell.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present.
Shares of EXAS have lost 15% year to date. It beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 48.79%. Exact Sciences is expected to report Q2 results on Aug. 6, after market close.